Traphagen Investment Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
LMFP
CIM
CGH
CNB
AP
COPPSERS
Traphagen Investment Advisors's GILD Position: Q2 2026 in Review
Traphagen Investment Advisors sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 2,140 shares — an estimated $298K sold.
Traphagen Investment Advisors first reported a position in GILD in Q2 2019 and held it in 26 quarters. The position peaked at $17M in Q3 2022. 370 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Traphagen Investment Advisors reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
- Traphagen Investment Advisors sold 2,140 Gilead Sciences shares in Q2 2026, an estimated $298K.
- Traphagen Investment Advisors first reported a position in Gilead Sciences in Q2 2019 and held it in 26 quarters.
- Traphagen Investment Advisors's Gilead Sciences position peaked at $17M in Q3 2022.
- 370 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Traphagen Investment Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.